These observations, together with our results presented here, suggest that inhibiting CDK9 would suppress tumor-initiating embryonic stem cell transcription factors and survival proteins like Mcl1, to overcome NSCLC growth and drug resistance (Figure 8G, schematic). The gene discussed is CDK9; the disease is neoplasm.